Podcast Episodes

Back to Search
Ep. 369 - ASCO advances, China innovation & U.S. science under threat
Ep. 369 - ASCO advances, China innovation & U.S. science under threat

Season 7 Episode 369

Revolution Medicines continues to impress with more pancreatic cancer data, earning a standing ovation at ASCO over the weekend. On the latest BioCen…

5 months, 2 weeks ago

Short Long
View Episode
Ep. 368 - ASCO Preview, China Policy, ADC Linkers
Ep. 368 - ASCO Preview, China Policy, ADC Linkers

Season 7 Episode 368

At ASCO among presentations focused on pancreatic cancer innovation beyond KRAS; however, abstracts for the cancer conference also highlight ADCs, bi…

5 months, 3 weeks ago

Short Long
View Episode
Ep. 367 - FDA, obesity targets and the rise of DACs
Ep. 367 - FDA, obesity targets and the rise of DACs

Season 7 Episode 367

Marty Makary wasn’t the only official on the outs at FDA last week in another tumultuous turn of events for the regulatory agency. On the latest BioC…

6 months ago

Short Long
View Episode
Ep. 366 - Europe's need for speed: Bio€quity takeaways
Ep. 366 - Europe's need for speed: Bio€quity takeaways

Season 7 Episode 366

China’s speed in generating first-in-human data has catalyzed a race across the globe to reshape regulatory requirements to compete. BioCentury’s ana…

6 months, 1 week ago

Short Long
View Episode
Ep. 365 - Thin ice for Makary, redosing AAVs
Ep. 365 - Thin ice for Makary, redosing AAVs

Season 7 Episode 365

Marty Makary’s hold on the top job at FDA is slipping, with White House leaks about President Donald Trump’s displeasure with the FDA commissioner sh…

6 months, 1 week ago

Short Long
View Episode
Ep. 364 - UCB’s Candid buy, Grand Rounds and leukodystrophies
Ep. 364 - UCB’s Candid buy, Grand Rounds and leukodystrophies

Season 7 Episode 364

UCB is the latest biopharma player to consummate a multibillion-dollar deal amid a surge in biotech M&A activity, acquiring Ken Song’s Candid Therape…

6 months, 2 weeks ago

Short Long
View Episode
Ep. 363 - New targets at AACR, biopharma deals, Kurma fund
Ep. 363 - New targets at AACR, biopharma deals, Kurma fund

Season 7 Episode 653

More than 175 new oncology targets surfaced at this year’s American Association for Cancer Research annual meeting in San Diego, with the focus on ne…

6 months, 3 weeks ago

Short Long
View Episode
Ep. 362 - AACR: Data and de-risking
Ep. 362 - AACR: Data and de-risking

Season 7 Episode 362

Bispecific antibodies and dual-payload antibody-drug conjugates were in the spotlight at this year’s American Association for Cancer Research meeting…

6 months, 4 weeks ago

Short Long
View Episode
Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers
Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers

Season 7 Episode 361

The past week has delivered the largest M&A deal ever for a private, venture-backed biopharma, the second-largest follow-on ever for a NASDAQ-traded …

7 months ago

Short Long
View Episode
Ep. 360 - FDA’s FIH plans. Plus: billion-dollar deals, funds
Ep. 360 - FDA’s FIH plans. Plus: billion-dollar deals, funds

Season 7 Episode 360

A pathway proposed by FDA to cut the time it takes biopharma companies to get to first-in-human trials is more ambitious than similar policies in Aus…

7 months, 1 week ago

Short Long
View Episode

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us